- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Cytori Therapeutics Inc
+ Add to WatchlistCYTX:US
2.5000 USD 0.0700 2.72%As of 20:10:00 ET on 05/24/2013.
Snapshot for Cytori Therapeutics Inc (CYTX)
| Open: | 2.5200 | Day's Range: | 2.4800 - 2.5600 | Volume: | 110,793 |
|---|---|---|---|---|---|
| Previous Close: | 2.5000 | 52wk Range: | 2.0600 - 4.9300 | 1-Yr Rtn: | +14.68% |
Key Statistics for CYTX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.4900 |
| Est. EPS (USD) (12/2013) | -0.4400 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 167.96 |
| Shares Outstanding (M) | 67.18 |
| 30 Day Average Volume | 238,090 |
| Price/Book (mrq) | 70.9175 |
| Price/Sale (ttm) | 9.0570 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CYTX
Company Profile & Key Executives for CYTX
Cytori Therapeutics, Inc. discovers and develops cell-based therapeutics utilizing adult stem cells derived from fat tissue. The Company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery.
| Christopher J CalhounCEO/Co-Founder | Marc H HedrickPresident |
| Mark E SaadChief Financial Officer | Seijiro Norio ShirahamaPresident:Asia Pacific |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CYTX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page